BC Innovations | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BC Extra | Apr 14, 2015
Politics & Policy

Regulators support C-Path's skeletal muscle biomarkers

FDA and EMA issued Letters of Support for four skeletal muscle biomarkers identified by the Predictive Safety Testing Consortium (PSTC) of the Critical Path Institute (C-Path). Elevated levels of myosin light chain 3 ( MYL3 ),...
BC Innovations | Jul 11, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Fatty acid binding protein 5 psoriasis-associated (FABP5; EFABP) In vitro and mouse studies suggest FABP5 inhibition could help treat breast cancer. In mouse...
BC Innovations | Jun 6, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Fatty acid binding protein 4 adipocyte (FABP4) In vitro and mouse studies suggest blocking FABP4 could help treat diabetes. In primary hepatocytes and...
BC Week In Review | Feb 18, 2013
Clinical News

Omega-3 Cardiac Panel: Clinical trial started

Nanomix began a clinical trial to evaluate its Omega-3 Cardiac Panel in about 170 healthy volunteers. Nanomix Inc. , Emeryville, Calif.   Product: Omega-3 Cardiac Panel   Business: Diagnostic   Molecular target: NA   Description: Mobile...
BC Innovations | Nov 10, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Ovarian cancer Fatty acid binding protein 4 adipocyte (FABP4) Patient tissue and mouse studies suggest inhibiting FABP4 could decrease ovarian cancer metastases. Ovarian cancer frequently...
BC Week In Review | Jun 27, 2011
Company News

Randox Laboratories Ltd. sales and marketing update

Randox launched an automated assay for heart-type fatty acid binding protein (H-FABP) worldwide to aid in the diagnosis and management of suspected acute coronary syndrome (ACS). The test has CE Mark approval in Europe. Randox...
BC Innovations | Mar 26, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Addiction; pain Fatty acid binding protein 5 brain (FABP5); FABP7 In vitro studies suggest that inhibiting FABPs could increase endocannabinoid...
BC Week In Review | Jun 18, 2007
Clinical News

Bristol-Myers preclinical data

Researchers published in Nature that BMS309403 reduced atherosclerotic lesions in mice by about 50% vs. controls. The compound also significantly increased insulin sensitivity and glucose metabolism vs. controls. BMS309403 inhibits adipocyte fatty-acid binding protein aP2...
BC Week In Review | Jun 4, 2001
Clinical News

Bristol-Myers preclinical data

BMY researchers and colleagues published in Nature Medicine that aP2 is expressed in macrophages (in addition to its previously reported expression in adipocytes), and is involved in the development of atherosclerosis. In a mouse model...
Items per page:
1 - 10 of 11